You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
The alliance will leverage Charleston, Veravas' sample prep technology and Tymora's extracellular vesicle enrichment technology.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
The IVD test will adjust for isatuximab-induced interference in immunofixation electrophoresis tests, which can mislead clinicians in interpreting patient response.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
As part of the collaboration, UNC will use the firm's BarreGen assay to target molecular changes to predict resistance or relapse following ablation.
Developers pointed to some success, but they also noted that more at-home tests need to demonstrate higher levels of performance and affordability.
The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.